← Back to diffwire
South Korea's Health Minister Announces Suspension of GLP-1 Drug Approvals
7 articles |
Updated 10h ago |
Created 1d ago
On March 16 at midnight (KST), the Ministry of Food and Drugs announced that it will not approve new licenses for drugs containing GLP-1 compounds due to safety concerns following a recent adverse event involving an infant death, according to Health Minister Lee Kyung-ha's statement on his official website. This decision follows reports from March 5 regarding complications in children under five who were prescribed the medication without parental consent or proper medical supervision by doctors at Seoul National University Hospital and other institutions nationwide.
Key Points
-
1The South Korean government has decided to ban the use of GLP-1 drugs for weight loss purposes.
-
2This decision follows a review by experts who identified significant health risks associated with these medications, including potential cardiovascular issues and kidney damage in children under six years old. The Ministry of Food and Drug Safety (MFDS) stated that while some benefits exist as part of diabetes treatment protocols due to their ability to lower blood sugar levels without causing hypoglycemia when combined appropriately.
-
3The ban applies specifically to the use case for weight loss, not affecting other medical applications where these drugs are prescribed under strict supervision by healthcare professionals.
Developments
[Mar 16]
Government announced final decision on GLP-1 ban; experts cited health risks including heart and kidney damage in children. The Ministry of Food and Drug Safety (MFDS) confirmed the restriction applies to weight loss use only.
[Mar 15, 23:47]
Experts at a government meeting concluded that GLP-1 drugs pose serious health risks for children under six years old due to potential cardiovascular and kidney damage. They recommended restricting usage solely within diabetes treatment protocols.
[Mar 15, 23:40]
The Ministry of Food and Drug Safety (MFDS) officially decided on the ban after reviewing expert opinions regarding health risks associated with GLP-1 drugs for weight loss purposes. The decision aims to prioritize patient safety over commercial interests.
[Mar 15, 23:40]
Experts at a government meeting concluded that children under six years old face serious health risks from GLP-1 drugs due to potential cardiovascular and kidney damage. They recommended restricting usage solely within diabetes treatment protocols.
[Mar 15, 23:40]
Experts at a government meeting concluded that children under six years old face serious health risks from GLP-1 drugs due to potential cardiovascular and kidney damage. They recommended restricting usage solely within diabetes treatment protocols.